Brilinta

How AstraZeneca Will Use A Diagnostic To Market Its Blood Thinner

How AstraZeneca Will Use A Diagnostic To Market Its Blood Thinner

Forbes

Can Pascal Soriot Turn Around AstraZeneca? It May Come Down To One Drug

Can Pascal Soriot Turn Around AstraZeneca? It May Come Down To One Drug

Forbes

AstraZeneca In Strong Position With Brilinta

AstraZeneca In Strong Position With Brilinta

Seeking Alpha

AstraZeneca Expands Study Of Brilinta Against Plavix

AstraZeneca Expands Study Of Brilinta Against Plavix

Bloomberg

With Plavix gone generic, payers aim to cut Effient, Brilinta

With Plavix gone generic, payers aim to cut Effient, Brilinta

Fierce Pharma

Germany gives final OK to AstraZeneca heart drug

Germany gives final OK to AstraZeneca heart drug

Reuters

Payer Negotiation is Next Up for AstraZeneca

Payer Negotiation is Next Up for AstraZeneca

WSJ Online

Is AstraZeneca Overcharging For Its Bloodthinner?

Is AstraZeneca Overcharging For Its Bloodthinner?

Pharmalot

AstraZeneca Sets Premium Price for Ticagrelor (Brilinta)

AstraZeneca Sets Premium Price for Ticagrelor (Brilinta)

Forbes